Araştırma Makalesi

Investigation of The Effect of B-108 Contaınıng Azomethin Group On DNA Repair Gene

Cilt: 44 Sayı: 4 31 Aralık 2022
Cumhuriyet Tıp Dergisi Kapak
Cumhuriyet Tıp Dergisi
PDF İndir
EN

Investigation of The Effect of B-108 Contaınıng Azomethin Group On DNA Repair Gene

Abstract

Objective: Cancer arises as a result of the failure of the mechanisms controlling normal division in a group of cells. It is known that some new synthesis compounds intended for use in cancer treatment have anti-fungal, anti-bacterial, anti-carcinogenic effects. In this study, it was aimed to apply the newly synthesized B-108 compound to the A-549 cell line and then to investigate the effect of this compound on the ERCC1 gene expression profile. Materials and Methods: Firstly, compound B-108 was synthesized in our study. Afterwards, this synthesized molecule was applied in eight different concentrations (1-100 μg/ml) in A-549 cell line and 3-(4,5-dimethylthiazol-2-yl)-2,5-yl for 24 hours, 48 hours and 72 hours. Anticancer activities were determined using diphenyltetrazolium bromide (MTT) method. Expression level of DNA repair gene (ERCC1) was determined using RT-PCR method. Results: As a result, it was determined that the molecule applied to the A-549 cell line showed the highest activity after 72 hours of incubation. It was observed that the ERCC1 gene expression of the molecule applied on lung cancer was lower than the control group. Discussion: Considering the current study results, low expression of ERCC1 shows that compound B-108 correlates with overall survival on lung cancer cells.

Keywords

Kaynakça

  1. Bray, F., et al., Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. 2018. 68(6): p. 394-424.
  2. Kasper, D., et al., Harrison's principles of internal medicine, 19e. Vol. 1. 2015: Mcgraw-hill New York, NY, USA.
  3. Travis, W.D., E. Brambilla, and G.J.J.J.C.O. Riely, New pathologic classification of lung cancer: relevance for clinical practice and clinical trials. 2013. 31(8): p. 992-1001.
  4. Bunn, P.A., Jr., Triplet combination chemotherapy and targeted therapy regimens. Oncology (Williston Park), 2001. 15(3 Suppl 6): p. 26-32.
  5. Schabath, M.B., M.L.J.C.e. Cote, biomarkers, and prevention, Cancer progress and priorities: lung cancer. 2019. 28(10): p. 1563-1579.
  6. Scagliotti, G., et al., Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol, 2010. 28(11): p. 1835-42.
  7. Ciccia, A. and S.J. Elledge, The DNA damage response: making it safe to play with knives. Mol Cell, 2010. 40(2): p. 179-204.
  8. Rosell, R., et al., Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. 2012. 13(3): p. 239-246.

Ayrıntılar

Birincil Dil

İngilizce

Konular

Sağlık Kurumları Yönetimi

Bölüm

Araştırma Makalesi

Yazarlar

Elif Eğilmez
0000-0003-1125-7939
Türkiye

Alakbar Huseynzada
0000-0002-6342-4260
Azerbaijan

Ulviyya Hasanova
0000-0003-1502-4227
Azerbaijan

Yayımlanma Tarihi

31 Aralık 2022

Gönderilme Tarihi

11 Kasım 2022

Kabul Tarihi

19 Aralık 2022

Yayımlandığı Sayı

Yıl 2022 Cilt: 44 Sayı: 4

DOI

https://doi.org/10.7197/cmj.1189765

IZ

https://izlik.org/JA89HL89EA

Kaynak Göster

RIS / Bibtex
AMA
1.Eğilmez E, Zontul C, Huseynzada A, vd. Investigation of The Effect of B-108 Contaınıng Azomethin Group On DNA Repair Gene. CMJ. 2022;44(4):338-342. doi:10.7197/cmj.1189765